Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 2 Study Evaluating Abiraterone Acetate With Different Steroid Regimens for Preventing Symptoms Associated With Mineralocorticoid Excess in Asymptomatic, Chemotherapy-naïve and Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients

NCT01867710 is registered in ClinicalTrials.gov with Janssen Pharmaceutica N.V., Belgium as lead sponsor.

NCT NCT01867710
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01867710 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 2 Study Evaluating Abiraterone Acetate With Different Steroid Regimens for Preventing Symptoms Associated With Mineralocorticoid Excess in Asymptomatic, Chemotherapy-naïve and Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients
Lead sponsor
Janssen Pharmaceutica N.V., Belgium
Phase
Phase 2
Overall status
Completed
Start date
July 16, 2013
Completion date
June 5, 2018
Enrollment
164 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer